The company Johnson & Johnson has claimed that its single-shot vaccine for coronavirus can neutralize the highly infectious delta variant and give durable protection against coronavirus infection. On July 1, J&J said in a statement that those who had received its vaccine produced powerful neutralizing antibodies over the period of at least eight months. The antibodies worked against all variants, including the deadly delta variant, which now has spread all across the globe.
Delta variant is expected to be the most dominant strain in the United States, according to the CDC. The J&J vaccination shot provides less protection at the beginning than the m-RNA vaccine from Moderna and Pfizer. The experts are discussing whether few people need booster shots in order to keep the coronavirus at bay. The J&J head of infectious diseases and vaccines, Johan Van Hoof, said that they are extremely happy and confident to say there is no requirement for the booster at present, and the vaccines are protected against several strains.
The company said that the shot of the vaccine neutralized the delta variant in 29 days of the single dose, and the protection improves as well as mature over time. Van Hoof said Johnson and Johnson do not believe that people who are given the first dose of its vaccine should not require any other booster within a year after getting it. He further added that even if a boost is needed, they do not think they will make any changes in the formulation.
Scientists, as well as some vaccine manufacturers, are crafting new or updated versions of the vaccine shots to directly target all the emerging variants. The emerging variants that have proved more transmissible than the actual virus are highly aimed to neutralize through vaccination shots.
The Findings disclosed by Johnson & Johnson
On July 1, J&J disclosed the findings from two studies. The company analyzed the eight participants’ blood samples in its late-stage vaccine clinical trial. There they wanted to assess the neutralizing antibodies generated against the infectious delta variant. Beth Israel Deaconess Medical Center’s Dan Barouch evaluated the immune response durability in 20 participants in an earlier stage vaccine study. The company has said that more robust results are going to be published in an online research depository named bioRxiv. J&J is also studying the ability of its vaccine to produce T cells which can escalate its protective power.